Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma

July 6, 2026 updated by: Revolution Medicines, Inc.

Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib

This Expanded Access Program (EAP) is intended to provide daraxonrasib to eligible adult patients with previously treated metastatic pancreatic adenocarcinoma, who have no comparable or satisfactory alternative therapy and are unable to participate in an ongoing daraxonrasib clinical trial.

Study Overview

Status

Available

Conditions

Intervention / Treatment

Detailed Description

This EAP has been established to provide access to daraxonrasib to patients with previously treated metastatic pancreatic adenocarcinoma during the period before potential commercial availability. Patients may be eligible if they have progressed on, are intolerant of, or are no longer expected to benefit from available standard therapies, and if they are not able to enroll in a clinical trial of daraxonrasib due to ineligibility or lack of access. This EAP is intended to address an unmet medical need and is not designed to support clinical development objectives.

Daraxonrasib is an investigational, orally administered, RAS(ON) inhibitor administered as monotherapy. Daraxonrasib will be supplied by the Sponsor free of charge during the duration of treatment under this program.

Study Type

Expanded Access

Expanded Access Type

  • Treatment IND/Protocol

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Puerto Rico
      • San Juan, Puerto Rico, 00909
        • Available
        • PanOncology Centre
  • United States
    • Alabama
      • Daphne, Alabama, United States, 36526
        • Available
        • Southern Cancer Center
      • Mobile, Alabama, United States, 36608
        • Available
        • Southern Cancer Center
    • Alaska
      • Anchorage, Alaska, United States, 99508
        • Available
        • Alaska Oncology and Hematology
    • Arizona
      • Scottsdale, Arizona, United States, 85258
        • Available
        • Honor Health
    • California
      • Chula Vista, California, United States, 91911
        • Available
        • Care Oncology Center
      • Duarte, California, United States, 91010
        • Available
        • City of Hope Cancer Center (California)
      • Los Angeles, California, United States, 90048
        • Available
        • Cedars-Sinai Medical Center
      • Los Angeles, California, United States, 90095
        • Available
        • University of California
      • Los Angeles, California, United States, 90033
        • Available
        • USC Norris Comprehensive Cancer Hospital
      • Los Angeles, California, United States, 90095
        • Available
        • UCLA Health Westlake Village
      • Mountain View, California, United States, 94040
        • Available
        • El Camino Health
      • Roseville, California, United States, 95661
        • Available
        • The Kaiser Permanente Medical Group
      • Sacramento, California, United States, 95816
        • Available
        • Sutter Health
      • San Francisco, California, United States, 94115
        • Available
        • Sutter Health
      • Vacaville, California, United States, 95687
        • Available
        • NorthBay Health Heidi Y Campini Cancer Center
      • Walnut Creek, California, United States, 94598
        • Available
        • UCSF John Muir Health
    • Colorado
      • Aurora, Colorado, United States, 80012
        • Available
        • Rocky Mountain Cancer Center
      • Durango, Colorado, United States, 81301
        • Available
        • CommonSpirit Oncology Mercy
    • Florida
      • Boca Raton, Florida, United States, 33487
        • Available
        • Lynn Cancer Institute - Boca Raton Regional Hospital
      • Hollywood, Florida, United States, 33021
        • Available
        • Memorial Cancer Institute
      • Jacksonville, Florida, United States, 32224
        • Available
        • Mayo Clinic - Florida
      • Miami, Florida, United States, 33176
        • Available
        • Baptist Hospital of Miami
      • Miami, Florida, United States, 33136
        • Available
        • Sylvester Comprehensive Cancer Center
      • Miami Beach, Florida, United States, 33140
        • Available
        • Mount Sinai Medical Center of Florida
      • Tampa, Florida, United States, 33612
        • Available
        • Moffitt Cancer Center
    • Hawaii
      • Honolulu, Hawaii, United States, 96813
        • Available
        • The Queen's Medical Center
    • Illinois
      • Arlington Heights, Illinois, United States, 60005
        • Available
        • Illinois Cancer Specialist
    • Iowa
      • Waukee, Iowa, United States, 50263
        • Available
        • University of Iowa
    • Kansas
      • Merriam, Kansas, United States, 66204
        • Available
        • Advent Health Shawnee Mission
      • Westwood, Kansas, United States, 66205
        • Available
        • University of Kansas Medical Center
      • Wichita, Kansas, United States, 67214
        • Available
        • Cancer Center of Kansas
    • Kentucky
      • Lexington, Kentucky, United States, 40503
        • Available
        • Baptist Health Lexington
    • Louisiana
      • New Orleans, Louisiana, United States, 70112
        • Available
        • LSU LCMC Health Cancer Center
    • Maine
      • Topsham, Maine, United States, 04086
        • Available
        • New England Cancer Specialists
    • Maryland
      • Baltimore, Maryland, United States, 21231
        • Available
        • Johns Hopkins
    • Massachusetts
      • Boston, Massachusetts, United States, 02215
        • Available
        • Beth Israel Deaconess Medical Center
      • Boston, Massachusetts, United States, 02215
        • Available
        • Dana Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Available
        • University of Michigan
      • Detroit, Michigan, United States, 48201
        • Available
        • Karmanos Cancer Institute (Barbara Ann Karmanos Cancer Hospital)
      • Detroit, Michigan, United States, 48202
        • Available
        • Henry Ford Health
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Available
        • Mayo Clinic Minnesota
      • Saint Louis Park, Minnesota, United States, 55426
        • Available
        • Park Nicollet Specialty Center
      • Saint Paul, Minnesota, United States, 55101
        • Available
        • Health Partners Oncology
    • Missouri
      • Kansas City, Missouri, United States, 64111
        • Available
        • Saint Luke's Hospital of Kansas City
      • Kansas City, Missouri, United States, 64132
        • Available
        • Mid America Cancer Care
      • St Louis, Missouri, United States, 63141
        • Available
        • Washington University School of Medicine
    • Nebraska
      • Omaha, Nebraska, United States, 68130
        • Available
        • Nebraska Cancer Specialists
    • New Jersey
      • Morristown, New Jersey, United States, 07960
        • Available
        • Overlook Medical Center - Medical Diagnostic Associates - Atlantic Medical Group
    • New York
      • Brooklyn, New York, United States, 11206
        • Available
        • Hirschfeld Oncology
      • Long Island City, New York, United States, 11101
        • Available
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, United States, 10016
        • Available
        • NYU Langone Health
      • New York, New York, United States, 10029
        • Available
        • The Mount Sinai Hospital
      • The Bronx, New York, United States, 10461
        • Available
        • Montefiore Medical Center
    • North Carolina
      • Durham, North Carolina, United States, 27710
        • Available
        • Duke Cancer Institute
      • Huntersville, North Carolina, United States, 28078
        • Available
        • Carolina BioOncology Institute
    • Ohio
      • Columbus, Ohio, United States, 43219
        • Available
        • Zangmeister Cancer Center
      • Dayton, Ohio, United States, 45459
        • Available
        • Premier Health OH
      • Middletown, Ohio, United States, 45005
        • Available
        • Premier Health OH
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73120
        • Available
        • Mercy Hospital Oklahoma City
    • Oregon
      • Salem, Oregon, United States, 97301
        • Available
        • Oregon Oncology Specialists
    • Pennsylvania
      • Dunmore, Pennsylvania, United States, 18512
        • Available
        • Hematology & Oncology Associates of NEPA
      • Philadelphia, Pennsylvania, United States, 19107
        • Available
        • Thomas Jefferson University Hospital
      • Sayre, Pennsylvania, United States, 18840
        • Available
        • Guthrie Sayre
    • South Dakota
      • Sioux Falls, South Dakota, United States, 57105
        • Available
        • Avera Cancer Institute
    • Tennessee
      • Germantown, Tennessee, United States, 38138
        • Available
        • West Cancer Center
      • Nashville, Tennessee, United States, 37203
        • Available
        • Sarah Cannon Cancer Institute
    • Texas
      • Houston, Texas, United States, 77030
        • Available
        • MD Anderson Cancer Center
    • Washington
      • Renton, Washington, United States, 98057
        • Available
        • Seattle Integrative Cancer Center
      • Seattle, Washington, United States, 98101
        • Available
        • Virginia Mason Medical Center
      • Seattle, Washington, United States, 98104
        • Available
        • Swedish Cancer Institute Treatment Center
    • Wisconsin
      • Marshfield, Wisconsin, United States, 54449
        • Available
        • Marshfield Medical Center
      • Milwaukee, Wisconsin, United States, 53226
        • Available
        • Medical College of Wisconsin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Description

Inclusion Criteria:

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed PDAC with metastatic disease.
  • Evidence of active disease progression during or following the most recent line of systemic therapy for PDAC, based on investigator assessment.
  • At least one prior line of systemic therapy in the metastatic setting, which must include either a fluoropyrimidine-based or gemcitabine-based regimen.
  • Received and progressed, been intolerant to prior standard therapy, or no longer expected to benefit from standard therapies.
  • Adequate bone marrow, renal, hepatic, and coagulation functions.
  • Ineligible for, or unable to enroll in, another clinical trial of daraxonrasib, if available.
  • Able to take oral medications

Exclusion Criteria:

  • History of known central nervous system metastatic disease.
  • Concurrent systemic anticancer therapy.
  • Significant cardiovascular disease.
  • Major GI conditions that may affect the ability to take or absorb daraxonrasib (patients with prior Whipple procedure are eligible).
  • Active uncontrolled systemic infection.
  • Major surgery within 28 days before enrollment.
  • Additional inclusion and exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Revolution Medicines, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

First Submitted

May 1, 2026

First Submitted That Met QC Criteria

May 1, 2026

First Posted (Actual)

May 7, 2026

Study Record Updates

Last Update Posted (Actual)

July 8, 2026

Last Update Submitted That Met QC Criteria

July 6, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RMC-6236-401

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Cancer

Clinical Trials on daraxonrasib

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe